Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences acquired in-process research and development (IPR&D) expenses ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Operations
Latest, FY2025
1,024
Period ended Dec 31, 2025
Change on a year earlier
-78.0%
4,663 in FY2024
History
8 years
Since FY2018
Sources
5
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Acquired in-process research and development (IPR&D) expenses ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,024 | -78.0% | Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗ |
| FY2024 | Dec 31, 2024 | 4,663 | +303.7% | Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗ |
| FY2023 | Dec 31, 2023 | 1,155 | +22.4% | Form 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗ |
| FY2022 | Dec 31, 2022 | 944 | +0.5% | Form 10-K (filed 2023-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 939 | -84.3% | Form 10-K (filed 2023-02-22) ↗ |
| FY2020 | Dec 31, 2020 | 5,968 | +40.4% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 4,251 | – | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 0 | – | Form 10-K (filed 2021-02-25) ↗ |
Breakdown
What makes up acquired in-process research and development (ipr&d) expenses ($m)
Cite this data
StockData. (2026). Gilead Sciences Acquired in-process research and development (IPR&D) expenses ($M) ($M), annual FY2018–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/iprd_acquired_exp
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.